Key facts
- This page summarizes John R. Moore's Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
- 10 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 14 Aug 2026, 16:53.
John R. Moore - 12 Aug 2026 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)
- Reporting relationship
- General Counsel
- Issuer ticker
- EWTX
- Reported as of
- 12 Aug 2026
- Net transaction value
- -$219,823
- SEC form
- 4
- Accepted by SEC
- 14 Aug 2026, 16:53:27 UTC
- Prior SEC filing
- 14 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ John R. Moore
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
John R. Moore filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 14 Aug 2026.
Change
- Previous filing in this sequence was filed on 14 Aug 2025.
- Current net transaction value: -$219,823.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001191702
Primary reporting owner
MOORE JOHN R
- Relationship
- General Counsel
- Address
- C/O EDGEWISE THERAPEUTICS, INC., 1715 38TH STREET, BOULDER
- Signature
- /s/ John R. Moore
- Signature date
- 14 Aug 2026
This filing has been restated.
Open the amended filing.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EWTX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +5,781
- Change %
- +57%
- Price
- $0.000000*
- Shares after
- 15,995
- Date
- 12 Aug 2026
- Ownership
- Direct
EWTX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +6,718
- Change %
- +42%
- Price
- $0.000000*
- Shares after
- 22,713
- Date
- 12 Aug 2026
- Ownership
- Direct
EWTX
transaction
Common Stock
Sale
- Transaction value
- $106,848
- Shares
- -2,439
- Change %
- -11%
- Price
- $43.81
- Shares after
- 20,274
- Date
- 12 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F2
EWTX
transaction
Common Stock
Sale
- Transaction value
- $2,620
- Shares
- -59
- Change %
- -0.29%
- Price
- $44.41
- Shares after
- 20,215
- Date
- 12 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F3
EWTX
transaction
Common Stock
Sale
- Transaction value
- $4,406
- Shares
- -99
- Change %
- -0.49%
- Price
- $44.50
- Shares after
- 20,116
- Date
- 12 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F4
EWTX
transaction
Common Stock
Sale
- Transaction value
- $105,949
- Shares
- -2,419
- Change %
- -12%
- Price
- $43.80
- Shares after
- 17,697
- Date
- 12 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EWTX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -5,781
- Change %
- -33%
- Price
- $0.000000*
- Shares after
- 11,563
- Date
- 12 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,781
- Exercise price
- $0.000000
- Footnotes
- F6
EWTX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -6,718
- Change %
- -25%
- Price
- $0.000000*
- Shares after
- 20,157
- Date
- 12 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,718
- Exercise price
- $0.000000
- Footnotes
- F7
EWTX
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- Shares
- +32,500
- Change %
- Price
- $0.000000*
- Shares after
- 32,500
- Date
- 12 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 32,500
- Exercise price
- $0.000000
- Footnotes
- F8
EWTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +65,000
- Change %
- Price
- $0.000000*
- Shares after
- 65,000
- Date
- 12 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 65,000
- Exercise price
- $0.000000
- Footnotes
- F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.
Footnote F2
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.22 to $44.18, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.40 to $44.42, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.41 to $44.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F5
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.33 to $44.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F6
Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
Footnote F7
Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
Footnote F8
Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
Footnote F9
1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.